Metastatic Breast Cancer With HER2 Positive (DBCOND0112973)

Identifiers

Synonyms

HER2-positive, Metastatic Breast Cancer / Metastatic HER2/Neu-positive Breast Cancer / HER2 Positive Metastatic Breast Cancers / Metastatic HER2-Positive Breast Cancer / Her2 Positive Metastatic Breast Cancer / Breast Cancer; HER2-positive; Metastatic / HER2-positive Metastatic Breast Cancer / HER-2 Positive Metastatic Breast Cancer / Metastasis from human epidermal growth factor 2 positive carcinoma of breast (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Margetuximab	An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.	Receptor tyrosine-protein kinase erbB-2target
Trastuzumab deruxtecan	An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer.	ATP-dependent translocase ABCB1transporter High affinity immunoglobulin gamma Fc receptor Itarget DNA topoisomerase 1target Lysosomal alpha-glucosidaseenzyme DNA topoisomerase 1enzyme Cathepsin Benzyme Procathepsin Lenzyme Cytochrome P450 3A4enzyme Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Multidrug and toxin extrusion protein 2transporter Multidrug resistance-associated protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Trastuzumab emtansine	An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.	Receptor tyrosine-protein kinase erbB-2target ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05018702	ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases	Anvatabart opadotin	treatment	2	unknown_status
NCT02025192	A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer	Capecitabine Trastuzumab Tucatinib	treatment	1	completed
NCT06435429	A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	Capecitabine Eribulin Gemcitabine Trastuzumab Vinorelbine Zanidatamab	treatment	3	recruiting
NCT02252887	Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy	Gemcitabine Pertuzumab Trastuzumab	treatment	2	active_not_recruiting
NCT03080805	Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)	Capecitabine Lapatinib Pyrotinib	treatment	3	unknown_status
NCT02422199	A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab	Capecitabine Lapatinib Pyrotinib	treatment	1 / 2	unknown_status
NCT04398108	A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC	Margetuximab	treatment	1	completed
NCT01495884	The Myocet/Lapatinib Study. ICORG 10-03, V5	Doxorubicin Lapatinib	treatment	1 / 2	terminated
NCT04681287	Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.	Inetetamab	treatment	2	active_not_recruiting
NCT03691051	A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer	Capecitabine Pyrotinib	treatment	2	active_not_recruiting
NCT02973737	A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer	Capecitabine Pyrotinib	treatment	3	active_not_recruiting
NCT04829604	ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)	Anvatabart opadotin	treatment	2	recruiting
NCT04784715	Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)	Pertuzumab Trastuzumab Trastuzumab deruxtecan	treatment	3	active_not_recruiting
NCT06551116	QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT06625775	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Trastuzumab	treatment	1	recruiting
NCT05868226	PRE-I-SPY Phase I/Ib Oncology Platform Program	Evorpacept Trastuzumab deruxtecan Tucatinib Zanidatamab	treatment	1	recruiting
NCT05036252	Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity	No drug interventions	Not Available	Not Available	recruiting
NCT05959291	Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer	No drug interventions	diagnostic	Not Available	recruiting
NCT06595563	HER2 Molecular Imaging with 89Zr-trastuzumab PET/CT As a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients with Advanced HER2-positive Breast Cancer	Trastuzumab emtansine	treatment	2	not_yet_recruiting
NCT06305702	Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer	Inetetamab	Not Available	Not Available	completed
NCT06278870	Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial	Disitamab vedotin Pertuzumab Pyrotinib Trastuzumab	treatment	3	recruiting
NCT04602117	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	Paclitaxel Trastuzumab duocarmazine	treatment	1	withdrawn
NCT04778982	Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer	Anbenitamab Fulvestrant Palbociclib	Not Available	Not Available	terminated
NCT03417544	Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC	Atezolizumab Pertuzumab Trastuzumab	treatment	2	active_not_recruiting
NCT05230810	Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.	Alpelisib Fulvestrant Tucatinib	treatment	1 / 2	recruiting
NCT06298084	Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd	Olaparib	treatment	1 / 2	recruiting
NCT05650879	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer	Trastuzumab deruxtecan Trastuzumab emtansine	treatment	1	recruiting
NCT05555251	BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	Trastuzumab	treatment	1 / 2	active_not_recruiting
NCT02605915	Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer	Atezolizumab Carboplatin Cyclophosphamide Docetaxel Doxorubicin Pertuzumab Trastuzumab Trastuzumab emtansine	treatment	1	completed
NCT06299852	Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer	Trastuzumab emtansine	treatment	Not Available	recruiting
NCT05800275	Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease	Capecitabine Trastuzumab Tucatinib	treatment	2	recruiting
NCT04385563	A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.	Docetaxel Trastuzumab	treatment	3	unknown_status
NCT03979339	Feasibility of a New Technology for Isolating Circulating Tumour Cells	No drug interventions	other	Not Available	unknown_status
NCT04319757	ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04692831	Testing a New Imaging Agent to Identify Cancer	Pertuzumab	diagnostic	1	recruiting
NCT05042791	A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases	Capecitabine Pyrotinib	treatment	2	recruiting
NCT05583110	Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer	Trastuzumab Tucatinib Vinorelbine	treatment	2	recruiting
NCT05188495	Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab	Pertuzumab Trastuzumab	Not Available	Not Available	unknown_status
NCT03617341	Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	unknown_status
NCT00146042	UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer	Docetaxel Trastuzumab	treatment	2	completed
NCT00810017	Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer	Etoposide Trastuzumab	treatment	2	terminated